The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
Open accessAbstract
Summary Background The Zika virus epidemic and associated congenital infections have prompted rapid vaccine development. We assessed two new DNA vaccines expressing premembrane and envelope Zika virus structural proteins. Methods We did two phase 1, randomised, open-label trials involving healthy adult volunteers. The VRC 319 trial, done in three centres, assessed plasmid VRC5288 (Zika virus and Japanese encephalitis virus chimera), and the VRC 320, done in one centre, assessed plasmid VRC5283 (wild-type Zika virus). Eligible participants were aged 18–35 years in VRC19 and 18–50 years in VRC 320. Participants were randomly assigned 1:1 by a computer-generated randomisation schedule prepared by the study statistician. All participants received intramuscular injection of 4 mg vaccine. In VRC 319 participants were assigned to receive vaccinations via needle and syringe at 0 and 8 weeks, 0 and 12 weeks, 0, 4, and 8 weeks, or 0, 4, and 20 weeks. In VRC 320 participants were assigned to receive vaccinations at 0, 4, and 8 weeks via single-dose needle and syringe injection in one deltoid or split-dose needle and syringe or needle-free injection with the Stratis device (Pharmajet, Golden, CO, USA) in each deltoid. Both trials followed up volunteers for 24 months for the primary endpoint of safety, assessed as local and systemic reactogenicity in the 7 days after each vaccination and all adverse events in the 28 days after each vaccination. The secondary endpoint in both trials was immunogenicity 4 weeks after last vaccination. These trials are registered with ClinicalTrials.gov, numbers NCT02840487 and NCT02996461. Findings VRC 319 enrolled 80 participants (20 in each group), and VRC 320 enrolled 45 participants (15 in each group). One participant in VRC 319 and two in VRC 320 withdrew after one dose of vaccine, but were included in the safety analyses. Both vaccines were safe and well tolerated. All local and systemic symptoms were mild to moderate. In both studies, pain and tenderness at the injection site was the most frequent local symptoms (37 [46%] of 80 participants in VRC 319 and 36 [80%] of 45 in VRC 320) and malaise and headache were the most frequent systemic symptoms (22 [27%] and 18 [22%], respectively, in VRC 319 and 17 [38%] and 15 [33%], respectively, in VRC 320). For VRC5283, 14 of 14 (100%) participants who received split-dose vaccinations by needle-free injection had detectable positive antibody responses, and the geometric mean titre of 304 was the highest across all groups in both trials. Interpretation VRC5283 was well tolerated and has advanced to phase 2 efficacy testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zika Virus Outbreak on Yap Island, Federated States of Micronesia
Duffy, M. R., Chen, T.-H., Hancock, W. T., Powers, A. M., Kool, J. L., Lanciotti, R. S., Pretrick, M., Marfel, M., Holzbauer, S., Dubray, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805715 · Cited by 3,132
Zika Virus (I). Isolations and serological specificity
Dick, G. W. A., Kitchen, S. F., & Haddow, A. J. (1952) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(52)90042-4 · Cited by 2,692
Zika Virus Outbreak, Bahia, Brazil
Campos, G. S., Bandeira, A. C., & Sardi, S. I. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2110.150847 · Cited by 1,146
Zika Virus in the Americas — Yet Another Arbovirus Threat
Fauci, A. S., & Morens, D. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1600297 · Cited by 1,069
Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever
Mongkolsapaya, J., Dejnirattisai, W., Xu, X.-N., Vasanawathana, S., Tangthawornchaikul, N., Chairunsri, A., Sawasdivorn, S., Duangchinda, T., Dong, T., Rowland-Jones, S., et al. (2003) · Nature Medicine · doi:10.1038/nm887 · Cited by 821
Evidence of Sexual Transmission of Zika Virus
D’Ortenzio, E., Matheron, S., de Lamballerie, X., Hubert, B., Piorkowski, G., Maquart, M., Descamps, D., Damond, F., Yazdanpanah, Y., & Leparc-Goffart, I. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1604449 · Cited by 716
Vaccine protection against Zika virus from Brazil
Larocca, R. A., Abbink, P., Peron, J. P. S., de A. Zanotto, P. M., Iampietro, M. J., Badamchi-Zadeh, A., Boyd, M., Ng’ang’a, D., Kirilova, M., Nityanandam, R., et al. (2016) · Nature · doi:10.1038/nature18952 · Cited by 505
Krauer, F., Riesen, M., Reveiz, L., Oladapo, O. T., Martínez-Vega, R., Porgo, T. V., Haefliger, A., Broutet, N. J., Low, N., & WHO Zika Causality Working Group (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002203 · Cited by 492
Davis, B. S., Chang, G.-J. J., Cropp, B., Roehrig, J. T., Martin, D. A., Mitchell, C. J., Bowen, R., & Bunning, M. L. (2001) · Journal of Virology · doi:10.1128/jvi.75.9.4040-4047.2001 · Cited by 447
Zika virus and microcephaly: why is this situation a PHEIC?
Heymann, D. L., Hodgson, A., Sall, A. A., Freedman, D. O., Staples, J. E., Althabe, F., Baruah, K., Mahmud, G., Kandun, N., Vasconcelos, P. F. C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00320-2 · Cited by 415
Cited by
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
The emergence of Zika virus and its new clinical syndromes
Pierson, T. C., & Diamond, M. S. (2018) · Nature · doi:10.1038/s41586-018-0446-y · Cited by 391
Self-citationDNA vaccines: prime time is now
Gary, E. N., & Weiner, D. B. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.006 · Cited by 190
An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections
VanBlargan, L. A., Himansu, S., Foreman, B. M., Ebel, G. D., Pierson, T. C., & Diamond, M. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.082 · Cited by 123
Self-citationCOVID-19 vaccines: breaking record times to first-in-human trials
Kim, Y. C., Dema, B., & Reyes-Sandoval, A. (2020) · npj Vaccines · doi:10.1038/s41541-020-0188-3 · Cited by 117
Metadata
- Authors
- Gaudinski, M. R., Houser, K. V., Morabito, K. M., Hu, Z., Yamshchikov, G., Rothwell, R. S., Berkowitz, N., Mendoza, F., Saunders, J. G., Novik, L., Hendel, C. S., Holman, L. A., Gordon, I. J., Cox, J. H., Edupuganti, S., McArthur, M. A., Rouphael, N. G., Lyke, K. E., Cummings, G. E., Sitar, S., Bailer, R. T., Foreman, B. M., Burgomaster, K., Pelc, R. S., Gordon, D. N., DeMaso, C. R., Dowd, K. A., Laurencot, C., Schwartz, R. M., Mascola, J. R., Graham, B. S., Pierson, T. C., Ledgerwood, J. E., Chen, G. L., Plummer, S., Costner, P., Zephir, K., Casazza, J., Ola, A., Victorino, M., Levinson, C., Whalen, W., Wang, X., Cunningham, J., Vasilenko, O., Burgos Florez, M., Hickman, S., Pittman, I., Le, L., Larkin, B., Andrews, C., Apte, P., Hicks, R., Trelles Cartagena, C., Williams, P., Boyd, C. R., Conan-Cibotti, M., Stein, J., Kaltovich, F., DeCederfelt, H., McAdams, S., Renehan, P., Chen, W., Greenberg, N., Wymer, N., Wadsworth, L., Billington, M., Robinson, T., Boyce, C., Pa'ahana Brown, F., Chrisley, L., Kwon, A., Patel, P., Kominou, P., Dorsey, B., Eddington, S., Telscher, S., Lee, M., Mosely, R., Ross, A., Ford, G., Domjahn, B., Xu, J., Beck, A., Fineman, R., Heeke, S., Winter, J., Nagar, S., Kelley, C., Mulligan, M., Plummer, S., Costner, P., Zephir, K., Casazza, J., Ola, A., Victorino, M., Levinson, C., Whalen, W., Wang, X., Cunningham, J., Vasilenko, O., Burgos Florez, M., Hickman, S., Pittman, I., Le, L., Larkin, B., Andrews, C., Apte, P., Hicks, R., Trelles Cartagena, C., Williams, P., Boyd, C. R., Conan-Cibotti, M., Stein, J., Kaltovich, F., DeCederfelt, H., McAdams, S., & Renehan, P.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 391
- Issue
- 10120
- Pages
- 552-562
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2771101851
- Cited by
- 301
- References
- 29
- FWCI
- 32.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. https://app.cochat.ai/papers/10.1016/s0140-6736(17)33105-7
- The paper
- Gaudinski, M. R., Houser, K. V., Morabito, K. M., Hu, Z., Yamshchikov, G., Rothwell, R. S., Berkowitz, N., Mendoza, F., Saunders, J. G., Novik, L., Hendel, C. S., Holman, L. A., Gordon, I. J., Cox, J. H., Edupuganti, S., McArthur, M. A., Rouphael, N. G., Lyke, K. E., Cummings, G. E., . . . Renehan, P. (2018). Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. The Lancet. https://doi.org/10.1016/s0140-6736(17)33105-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.